Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours

The anti-Epidermal Growth Factor Receptor (EGFR) antibody Cetuximab (CTX) has demonstrated limited anti-cancer efficacy in cells overexpressing EGFR due to activating mutations in RAS in solid tumours, such as pancreatic cancer. The utilisation of antibodies as targeting components of antibody-drug...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nanoscale
Hlavní autoři: McDaid, William J., Greene, Michelle K., Johnston, Michael C., Pollheimer, Ellen, Smyth, Peter, McLaughlin, Kirsty, Van Schaeybroeck, Sandra, Straubinger, Robert M., Longley, Daniel B., Scott, Christopher J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6861736/
https://ncbi.nlm.nih.gov/pubmed/31626255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1039/c9nr07257h
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky